Roche sizes up first BTK inhibitor approval on Phase III MS victory
If fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.
If fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.
Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal